| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 461.985 | 522.867 | 329.449 | 701.926 | 514.723 | 998.696 | 491.523 | 567.349 | 898.944 | 810.291 |
| Total Income - EUR | 463.589 | 524.128 | 335.126 | 726.525 | 519.567 | 1.007.735 | 492.672 | 572.057 | 900.629 | 812.134 |
| Total Expenses - EUR | 357.499 | 403.178 | 277.157 | 507.597 | 416.221 | 719.050 | 419.169 | 467.592 | 732.087 | 635.117 |
| Gross Profit/Loss - EUR | 106.089 | 120.950 | 57.969 | 218.928 | 103.346 | 288.685 | 73.503 | 104.465 | 168.542 | 177.017 |
| Net Profit/Loss - EUR | 87.200 | 99.598 | 48.559 | 211.683 | 98.163 | 279.314 | 68.677 | 98.895 | 147.032 | 149.197 |
| Employees | 7 | 8 | 9 | 9 | 8 | 8 | 7 | 6 | 6 | 6 |
Check the financial reports for the company - Novel Research Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 10.476 | 5.339 | 5.666 | 28.837 | 8.509 | 5.935 | 7.590 | 6.848 | 8.823 | 6.922 |
| Current Assets | 266.727 | 308.264 | 261.351 | 602.522 | 400.116 | 604.389 | 394.798 | 234.064 | 432.906 | 282.130 |
| Inventories | 2.706 | 2.619 | 5.647 | 4.277 | 1.300 | 3.391 | 1.071 | 2.773 | 1.832 | 1.343 |
| Receivables | 53.885 | 77.842 | 91.832 | 413.714 | 175.303 | 290.522 | 163.439 | 137.501 | 233.251 | 95.545 |
| Cash | 210.136 | 227.804 | 163.871 | 184.531 | 223.513 | 310.475 | 230.287 | 93.790 | 197.823 | 185.243 |
| Shareholders Funds | 160.713 | 155.804 | 105.140 | 265.924 | 151.354 | 331.496 | 119.702 | 150.078 | 198.060 | 199.940 |
| Social Capital | 45 | 62 | 61 | 60 | 59 | 58 | 57 | 57 | 57 | 56 |
| Debts | 116.489 | 161.917 | 162.407 | 372.067 | 272.247 | 283.434 | 285.705 | 94.222 | 244.043 | 89.152 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7320 - 7320" | |||||||||
| CAEN Financial Year |
7320
|
|||||||||
Comments - Novel Research Srl